Plain-English translation of NCT07671339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination approach for pancreatic cancer: standard chemotherapy () paired with a new vaccine called that teaches the immune system to recognize and attack cancer cells. Some participants will also receive an additional immunotherapy drug () to further boost the immune response. The goal is to help shrink tumors before surgery and prevent cancer from coming back.
Pancreatic cancer is difficult to treat, and current approaches don't work well enough for many patients. Researchers hope that combining chemotherapy with this new vaccine approach will give patients' immune systems a better chance to fight the cancer and improve survival.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy () combined with the new vaccine () over several months. Depending on which group you're assigned to, you may also receive an additional immunotherapy medication () by IV infusion every four weeks. You'll have regular clinic visits for treatment administration, blood tests to monitor your health, and imaging scans to see how the cancer is responding. After the initial treatment phase, you may proceed to surgery if appropriate, followed by continued monitoring.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States